Endocannabinoid system and mood disorders: Priming a target for
new therapies

J 2013

Endocannabinoid system and mood disorders: Priming a target for new therapies

MICALE, Vincenzo, Vincenzo DI MARZO, Alexandra ŠULCOVÁ, Carsten T. WOTJAK, Filippo DRAGO et. al.

Basic information

Original name

Endocannabinoid system and mood disorders: Priming a target for new therapies

Authors

MICALE, Vincenzo (380 Italy, guarantor, belonging to the institution), Vincenzo DI MARZO (380 Italy), Alexandra ŠULCOVÁ (203 Czech Republic, belonging to the institution), Carsten T. WOTJAK (276 Germany) and Filippo DRAGO (380 Italy)

Edition

Pharmacology & Therapeutics, Oxford, UK, PERGAMON-ELSEVIER SCIENCE LTD, 2013, 0163-7258

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 7.745

RIV identification code

RIV/00216224:14740/13:00067765

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1016/j.pharmthera.2012.12.002

UT WoS

000316520600002

Keywords in English

Endocannabinoid system; CB1 receptors; TRPV1 channels; Animal models; Anxiety; Depression

Abstract

V originále

The endocannabinoid system (ECS), comprising two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle delta 9-tetrahydrocannabinol [delta 9-THC]), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and degradation, has been suggested as a pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiopathological conditions. In the brain activation of this system modulates the release of excitatory and inhibitory neurotransmitters and of cytokines from glial cells. As such, the ECS is strongly involved in neuropsychiatric disorders, particularly in affective disturbances such as anxiety and depression. It has been proposed that synthetic molecules that inhibit endocannabinoid degradation can exploit the selectivity of endocannabinoid action, thus activating cannabinoid receptors only in those tissues where there is perturbed endocannabinoid turnover due to the disorder, and avoiding the potential side effects of direct CB1 and CB2 activation. However, the realization that endocannabinoids, and AEA in particular, also act at other molecular targets, and that these mediators can be deactivated by redundant pathways, has recently led to question the efficacy of such approach, thus opening the way to new multi-target therapeutic strategies, and to the use of non-psychotropic cannabinoids, such as cannabidiol (CBD), which act via several parallel mechanisms, including indirect interactions with the ECS. The state of the art of the possible therapeutic use of endocannabinoid deactivation inhibitors and phytocannabinoids in mood disorders is discussed in this review article.

Links

ED1.1.00/02.0068, research and development project

Name: CEITEC - central european institute of technology

Citovat

MICALE, Vincenzo, Vincenzo DI MARZO, Alexandra ŠULCOVÁ, Carsten T. WOTJAK and Filippo DRAGO. Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacology & Therapeutics. Oxford, UK: PERGAMON-ELSEVIER SCIENCE LTD, 2013, vol. 138, No 1, p. 18-37. ISSN 0163-7258. Available from: https://dx.doi.org/10.1016/j.pharmthera.2012.12.002.

@article{1086858,
   author = {Micale, Vincenzo and Di Marzo, Vincenzo and Šulcová, Alexandra and Wotjak, Carsten T. and Drago, Filippo},
   article_location = {Oxford, UK},
   article_number = {1},
   doi = {http://dx.doi.org/10.1016/j.pharmthera.2012.12.002},
   keywords = {Endocannabinoid system; CB1 receptors; TRPV1 channels; Animal models; Anxiety; Depression},
   language = {eng},
   issn = {0163-7258},
   journal = {Pharmacology & Therapeutics},
   title = {Endocannabinoid system and mood disorders: Priming a target for new therapies},
   url = {http://www.sciencedirect.com/science/article/pii/S0163725812002409},
   volume = {138},
   year = {2013}
}

TY  - JOUR
ID  - 1086858
AU  - Micale, Vincenzo - Di Marzo, Vincenzo - Šulcová, Alexandra - Wotjak, Carsten T. - Drago, Filippo
PY  - 2013
TI  - Endocannabinoid system and mood disorders: Priming a target for new therapies
JF  - Pharmacology & Therapeutics
VL  - 138
IS  - 1
SP  - 18-37
EP  - 18-37
PB  - PERGAMON-ELSEVIER SCIENCE LTD
SN  - 01637258
KW  - Endocannabinoid system
KW  - CB1 receptors
KW  - TRPV1 channels
KW  - Animal models
KW  - Anxiety
KW  - Depression
UR  - http://www.sciencedirect.com/science/article/pii/S0163725812002409
L2  - http://www.sciencedirect.com/science/article/pii/S0163725812002409
N2  - The endocannabinoid system (ECS), comprising two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle delta 9-tetrahydrocannabinol [delta 9-THC]), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and degradation, has been suggested as a pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiopathological conditions. In the brain activation of this system modulates the release of excitatory and inhibitory neurotransmitters and of cytokines from glial cells. As such, the ECS is strongly involved in neuropsychiatric disorders, particularly in affective disturbances such as anxiety and depression. It has been proposed that synthetic molecules that inhibit endocannabinoid degradation can exploit the selectivity of endocannabinoid action, thus activating cannabinoid receptors only in those tissues where there is perturbed endocannabinoid turnover due to the disorder, and avoiding the potential side effects of direct CB1 and CB2 activation. However, the realization that endocannabinoids, and AEA in particular, also act at other molecular targets, and that these mediators can be deactivated by redundant pathways, has recently led to question the efficacy of such approach, thus opening the way to new multi-target therapeutic strategies, and to the use of non-psychotropic cannabinoids, such as cannabidiol (CBD), which act via several parallel mechanisms, including indirect interactions with the ECS. The state of the art of the possible therapeutic use of endocannabinoid deactivation inhibitors and phytocannabinoids in mood disorders is discussed in this review article.
ER  -

MICALE, Vincenzo, Vincenzo DI MARZO, Alexandra ŠULCOVÁ, Carsten T. WOTJAK and Filippo DRAGO. Endocannabinoid system and mood disorders: Priming a target for new therapies. \textit{Pharmacology \&{} Therapeutics}. Oxford, UK: PERGAMON-ELSEVIER SCIENCE LTD, 2013, vol.~138, No~1, p.~18-37. ISSN~0163-7258. Available from: https://dx.doi.org/10.1016/j.pharmthera.2012.12.002.

Detailed Information on Publication Record